SciRhom Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $67.7M

  • Investors
  • 12

SciRhom General Information

Description

Developer of therapeutic antibodies designed to improve autoimmune disease therapies. The company creates antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signalings which is crucial for protecting the skin and intestinal barriers, enabling scientists to get better treatment options for life-threatening autoimmune diseases.

Contact Information

Website
www.scirhom.com
Formerly Known As
SciMab
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Am Klopferspitz 19
  • Planegg
  • 82152 Martinsried
  • Germany
+49 089
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Am Klopferspitz 19
  • Planegg
  • 82152 Martinsried
  • Germany
+49 089

SciRhom Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SciRhom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 09-Jul-2024 $67.7M Completed Pre-Clinical Trials
3. Later Stage VC 01-Jul-2023 Completed Pre-Clinical Trials
2. Seed Round 13-Dec-2021 $9M $17.9M Completed Pre-Clinical Trials
1. Seed Round 27-Oct-2016 $8.84M $8.84M Completed Pre-Clinical Trials
To view SciRhom’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

SciRhom Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic antibodies designed to improve autoimmune disease therapies. The company creates antibodies aga
Drug Discovery
Martinsried, Germany
12 As of 2023

Cambridge, MA

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SciRhom Competitors (123)

One of SciRhom’s 123 competitors is AnTolRx, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Venture Capital-Backed Cambridge, MA
Cullgen Pending Transaction (M&A) San Diego, CA
Plexium Venture Capital-Backed San Diego, CA
Anokion Venture Capital-Backed Ecublens, Switzerland
ImmunOs Therapeutics Venture Capital-Backed Schlieren, Switzerland
You’re viewing 5 of 123 competitors. Get the full list »

SciRhom Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 15

    Pending

  • Expiring in next 12 mo

SciRhom Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3213771-A1 Methods of treatment using protein binders to irhom2 epitopes Pending 29-Mar-2021
US-20240174744-A1 Methods of treatment using protein binders to irhom2 epitopes Pending 29-Mar-2021
AU-2022229740-A1 Humanized antibodies against irhom2 Pending 01-Mar-2021
CA-3208070-A1 Humanized antibodies against irhom2 Pending 01-Mar-2021
EP-4301778-A1 Humanized antibodies against irhom2 Pending 01-Mar-2021 C07K16/28
To view SciRhom’s complete patent history, request access »

SciRhom Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SciRhom Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
Bayern Kapital Venture Capital Minority
Hadean Ventures Venture Capital Minority
Kurma Partners Venture Capital Minority
MIG AG Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

SciRhom FAQs

  • When was SciRhom founded?

    SciRhom was founded in 2016.

  • Where is SciRhom headquartered?

    SciRhom is headquartered in Martinsried, Germany.

  • What is the size of SciRhom?

    SciRhom has 12 total employees.

  • What industry is SciRhom in?

    SciRhom’s primary industry is Drug Discovery.

  • Is SciRhom a private or public company?

    SciRhom is a Private company.

  • What is SciRhom’s current revenue?

    The current revenue for SciRhom is .

  • How much funding has SciRhom raised over time?

    SciRhom has raised $85.6M.

  • Who are SciRhom’s investors?

    Andera Partners, Bayern Kapital, Hadean Ventures, Kurma Partners, and MIG AG are 5 of 12 investors who have invested in SciRhom.

  • Who are SciRhom’s competitors?

    AnTolRx, Cullgen, Plexium, Anokion, and ImmunOs Therapeutics are some of the 123 competitors of SciRhom.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »